AstraZeneca has bought out diabetes partner Bristol-Myers Squibb for an upfront payment of $2.7 billion, potential milestones and asset transfers of of $1.6 billion, and royalty payments through 2025. The companies began their collaboration in diabetes in 2007 to develop and commercialize Onglyza and dapagliflozin. In July 2012, BMS and AZ worked together to acquire Amylin and its injectable diabetes treatments, Byetta, Bydureon and Symlin, for $5.3 billion. Under the terms of the deal, BMS wil...